Loading organizations...
§ Public · Berkeley Heights, NJ, USA
Clinical-stage biotechnology company developing hospital-based therapies for acute neurological conditions, focused on brain hemorrhages.
Founded in 2009 by scientific founders Frank Bedu-Addo and Gregory Conn, Edge Therapeutics was a clinical stage biotechnology company in Princeton, New Jersey, focused on developing hospital therapies for acute neurological conditions. The pre-revenue enterprise specifically targeted aneurysmal subarachnoid hemorrhages in critical care environments, advancing its lead candidate, a polymer microparticle of nimodipine called EG-1962, into Phase 3 clinical trials. Before this primary program ultimately failed in 2018, the business secured approximately $185 million in total funding across public and private markets. This extensive financial backing included a notable $72.5 million Series C financing round raised in 2015 under the guidance of President Brian Leuthner and Chairman Sol Barer. Following the clinical setback, leadership oversaw a strategic pivot that culminated in a March 2019 reverse merger with PDS Biotechnology Corporation to focus entirely on cancer immunotherapy platforms.
Edge Therapeutics has raised $84.0M across 3 funding rounds.
Edge Therapeutics has raised $84.0M in total across 3 funding rounds.
Edge Therapeutics has raised $84.0M across 3 funding rounds. Most recently, it raised $56.0M Series C in April 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2015 | $56M Series C | Anders Hove | 1955 Capital, Aberdare Ventures, Acorn Bioventures, Founders Fund, Highbury Group, Lightspeed Venture Partners, OrbiMed, Sequoia Capital, Sofinnova Investments, TED Driscoll, Biomed Ventures, Franklin Templeton, Janus Henderson Investors, NEW Leaf Venture Partners | Announced |
| Sep 8, 2014 | $10M Debt Financing | Hercules Capital | — | Announced |
| Jun 4, 2013 | $18M Series C | — | — | Announced |
Edge Therapeutics has raised $84.0M in total across 3 funding rounds.
Edge Therapeutics's investors include Anders Hove, 1955 Capital, Aberdare Ventures, Acorn Bioventures, Founders Fund, Highbury Group, Lightspeed Venture Partners, OrbiMed, Sequoia Capital, Sofinnova Investments, Ted Driscoll, BioMed Ventures.
Edge Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel, hospital-based therapies for acute, life-threatening neurological conditions, such as aneurysmal subarachnoid hemorrhage (aSAH) and chronic subdural hematoma.[1][3][4] Its lead product candidate, EG-1962, is a polymeric nimodipine microparticle delivered via the proprietary Precisa platform, designed to provide targeted, sustained drug release directly at the injury site, avoiding systemic side effects like hypotension associated with oral nimodipine.[3][4] The company serves patients in neurocritical care settings, addressing unmet needs in rare neurological disorders where current treatments fall short.[1][4] Edge raised over $100 million in funding, went public via IPO in 2015, but faced setbacks including trial discontinuations by 2018, leading to a reverse merger with PDS Biotechnology in late 2018.[5][6][7]
Founded in 2009 in Berkeley Heights, New Jersey, by Brian Leuthner (current/former CEO and President) and R. Loch Macdonald (Chief Scientific Officer), Edge Therapeutics emerged from a need to improve treatments for rare, acute neurological conditions underserved by existing therapies.[4][7] Leuthner and Macdonald leveraged their expertise in biotech and neurosurgery to pioneer targeted drug delivery; a pivotal moment came in June 2013 with promising preclinical results for EG-1962, a microparticle formulation for aSAH (ruptured brain aneurysms).[4] Early traction included a 2016 trademark filing for the Precisa platform, a biodegradable polymer technology enabling site-specific drug administration.[4] The company raised $72.5 million in Series C financing to advance EG-1962 toward Phase III trials and explore EG-1964 for chronic subdural hematoma prevention.[3]
Edge Therapeutics rode the wave of precision drug delivery innovations in biotech, targeting the growing neurocritical care market amid rising incidences of brain injuries—e.g., projected 60,000 annual U.S. chronic subdural hematoma cases by 2030.[4] Timing aligned with advances in polymer-based microparticles, differentiating from competitors like Imagine Pharmaceuticals (brain drug delivery) or OptiNose (nasal systems) by emphasizing intracranial, hospital-administered solutions.[5] Market forces favoring Edge included demand for therapies reducing ICU complications in aging populations and FDA interest in novel platforms for rare diseases.[3][4] Though its influence waned post-merger, Precisa exemplified how targeted delivery could disrupt neurological treatment ecosystems, inspiring similar platforms in cerebral aneurysm pipelines.[5]
Post-2018 reverse merger with PDS Biotechnology, Edge Therapeutics as an independent entity ceased, pivoting the combined firm toward cancer immunotherapies like Versamune, with Edge's neurological assets likely deprioritized amid R&D cuts and trial halts.[6][7] Looking ahead, Precisa's versatile tech could resurface in licensing deals for brain-targeted drugs, shaped by trends in personalized neurology and AI-optimized microparticles. Its legacy underscores biotech risks—strong early momentum undone by clinical setbacks—yet highlights potential for platform tech to evolve influence in neurotech mergers, tying back to Edge's original mission of transforming hospital care for brain injury survivors.[3][6]